Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > May 24, 2024
Daily News
May 24, 2024
- LDP’s Social Security Commission Urges Govt to Revisit Off-Year Drug Price Revisions
May 24, 2024
- JPMA, PhRMA, EFPIA to Jointly Survey Views on 2024 Drug Pricing Reform
May 24, 2024
- MHLW Proposes Inclusion of Prevenar 20 in National Immunization for Children
May 24, 2024
- AnGes to Roll Out Progeria Treatment Zokinvy on May 27
May 24, 2024
- Big 4 Wholesalers Log 11.7% Growth in Operating Profit, 3 Hit 1%-Plus Margins
May 24, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…